Organization
Pierre Louis Institute of Epidemiology and Public Health, PEPITES Team, Paris, France
2 abstracts
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES (RA-BE-REAL) – STUDY DESIGN AND BASELINE CHARACTERISTICSOrg: University Medicine Berlin, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, University of Florence, Division of Rheumatology, Florence, Italy, CHU de Reims, Traumatologie-Orthopédie, Reims, France, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, United States of America,
Abstract
A MULTINATIONAL, PROSPECTIVE, OBSERVATIONAL STUDY IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING BARICITINIB, TARGETED SYNTHETIC OR BIOLOGIC DISEASE-MODIFYING THERAPIES: 12 MONTH TIME TO DISCONTINUATION, EFFECTIVENESS AND PATIENT REPORTED OUTCOME DATA FROM THE EUROPEAN COHORTOrg: Schlosspark Klinik, Department of Internal Medicine and Rheumatology, Berlin, Germany, Charité Universitätsmedizin, Department of Rheumatology and Clinical Immunology, Indianapolis, United States of America, IRCCS San Raffaele Hospital, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milan, Italy, University of Florence and Division of Rheumatology AOUC, Department of Experimental and Clinical Rheumatology, Florence, Italy, Monash University and Emeritus Research, Cabrini Hospital, Melbourne, Australia,